Format

Send to

Choose Destination
See comment in PubMed Commons below
J Inorg Biochem. 2012 May;110:58-63. doi: 10.1016/j.jinorgbio.2012.02.012. Epub 2012 Feb 23.

Platinum(IV)-chlorotoxin (CTX) conjugates for targeting cancer cells.

Author information

1
Massachusetts Institute of Technology, Department of Chemistry, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.

Abstract

Cisplatin is one of the most widely used anticancer drugs. Its side effects, however, have motivated researchers to search for equally effective analogs that are better tolerated. Selectively targeting cancer tissue is one promising strategy. For this purpose, a platinum(IV) complex was conjugated to the cancer-targeting peptide chlorotoxin (CTX, TM601) in order to deliver cisplatin selectively to cancer cells. The 1:1 Pt-CTX conjugate was characterized by mass spectrometry and gel electrophoresis. Like most platinum(IV) derivatives, the cytotoxicity of the conjugate was lower in cell culture than that of cisplatin, but greater than those of its Pt(IV) precursor and CTX in several cancer cell lines.

PMID:
22465700
PMCID:
PMC3350571
DOI:
10.1016/j.jinorgbio.2012.02.012
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center